COSMETIC COMPOSITION COMPRISING THIOPYRIDINONE COMPOUNDS, A REDUCING AGENT AND ARGININE

Abstract

COSMETIC COMPOSITION COMPRISING THIOPYRIDINONE COMPOUNDS, A REDUCING AGENT, AND ARGININE. The present invention relates to a composition, preferably a cosmetic composition, comprising at least one thiopyridinone compound of formula (I) or formula (I'), with at least one reducing agent of formula (II) and arginine. The composition of the present invention lightens or depigments keratinous material, preferably skin. The present invention provides a composition including a thiopyridinone compound of formula (I) or formula (I') with increased stability of the thiopyridinone compound of formula (I) or formula (I') against exposure to light. Figure for the abstract: none

Description

Title of the invention: COSMETIC COMPOSITION COMPRISING THIOPYRIDINONE COMPOUNDS, A REDUCING AGENT AND ARGININE FIELD OF INVENTION

[0001] The present invention relates to the stabilization of thiopyridinone compounds in a composition comprising the thiopyridinone compound. The present invention also relates to cosmetic compositions for the whitening and depigmentation of a keratinous material, namely the skin. CONTEXT OF THE INVENTION

[0002] Many people develop brown spots or marks on their skin over the course of their lives, particularly on the face and hands. These brown spots or marks are due to the presence of a high concentration of melanin in the keratinocytes on the surface of the skin.

[0003] For the treatment of these pigmentation spots, there is a need for harmless topical depigmenting substances that offer good efficacy and can also have a skin-lightening effect. Certain organic compounds such as arbutin, niacinamide, and kojic acid are known as skin-depigmenting agents.

[0004] It is known that certain thiopyridinone compounds exhibit good depigmenting activity, even at low concentrations, for example those cited in documents WO2012 / 080075 and WO2017 / 102349. The thiopyridinone compound can show strong depigmenting or lightening effects by reducing melanin production. Nevertheless, there is a need to develop a cosmetic composition comprising a thiopyridinone compound with increased stability, to confer skin lightening and whitening effects. Summary of the invention

[0005] The inventors have surprisingly discovered that the combination of thiopyridinone compound(s) of formula (I) or (I'), arginine, and reducing agent(s) improves the stability, and preferably the photostability, of the compound of formula (I) or (I1) in the composition. In one aspect of the present invention, a composition, preferably a cosmetic composition, is proposed, comprising:

[0006] i) at least one compound selected from a compound of formula (I) below, its tautomer of formula (I') below, their salts, solvates, hydrates, optical isomers, racemates or mixtures thereof: OUASO ... 1 wy A'' N" zm, xK fL 'br S 1 H Formula (I) Formula (I')

[0007] in which,

[0008] - R i designates a radical chosen from:

[0009] a) a hydrogen atom;

[0010] b) a linear saturated alkyl group in the form of Ci-Cio or branched in the form of C3-CiO optionally substituted by one or more groups, which may be identical or different, selected from:

[0011] i)-O-R3;

[0012] ii) -S-R3;

[0013] - R 2 denotes a radical chosen from:

[0014] a) a hydrogen atom;

[0015] b) a linear saturated CrCi2 hydrocarbon group or a C3-Ci2 branched hydrocarbon group or a C3-C8 cyclic hydrocarbon group, optionally substituted by one or more groups, which may be identical or different, selected from

[0016] i) -O-R3;

[0017] ii) -S-R3;

[0018] iii) -C(O)-O-R3 ;

[0019] iv) an aryl group at C5-Ci2, optionally substituted by one or more hydroxyl groups and / or by one or more alkoxy radicals in CrC8 and

[0020] c) an aryl group in C5-Ci2, optionally substituted by one or more hydroxyls and / or with one or more alkoxy radicals in CrC8;

[0021] - R 3 designates a radical chosen from:

[0022] a) a hydrogen atom and

[0023] b) a linear saturated alkyl group in Ci-Cio or branched in C3-CiO;

[0024] ii) at least one reducing agent of formula (II), its mesomeric forms and its solvates such as hydrates

[0025] [Chem.l] O g ......... q " AT (II)

[0026] in which,

[0027] X represents a heteroatom chosen from oxygen or sulfur, preferably oxygen;

[0028] m is equal to 0 or 1;

[0029] M+ is a cation, preferably chosen from an alkali metal, an alkaline earth metal or an ammonium, more preferably chosen from an alkali metal such as sodium or potassium;

[0030] R represents a group chosen from:

[0031] i)-OH,

[0032] H) -O-M'+ with M'+ as defined previously for M+,

[0033] iii) o in which, [X'k

[0034] • p is an inclusive integer chosen between 0 and 4, preferably 0, 1, 2 and more preferably 0 or 2;

[0035] • m' is worth 0 or 1, preferably 1;

[0036] • X' is such that defined for X, preferably X' represents an oxygen atom; and

[0037] • M' '+ is such as defined previously for M+, and M+, M'+, M' '+ are identical or different, preferably identical;

[0038] and

[0039] iii) of arginine.

[0040] Another aspect of the present invention proposes a method for treating a keratinous material, the method comprising: the application of a composition comprising:

[0041] i) at least one compound selected from a compound of formula (I) below, its tautomer of formula (!') below, their salts, solvates, hydrates, optical isomers, racemates or mixtures thereof: O aA-''2 .L to, HO .. 1 ws JM Ki ■fU s 1 H Formula (I) Formula (I')

[0042] in which,

[0043] - R i designates a radical chosen from:

[0044] a) a hydrogen atom; and

[0045] b) a linear saturated alkyl group in the form of Ci-Cio or branched in the form of C3-CiO optionally substituted by one or more groups, which may be identical or different, selected from:

[0046] i) -O-R3 ; and

[0047] ii) -S-R3;

[0048] - R 2 designates a radical chosen from:

[0049] a) a hydrogen atom;

[0050] b) a linear saturated CrCi2 hydrocarbon group or a C3-Ci2 branched hydrocarbon group or a C3-C8 cyclic hydrocarbon group, optionally substituted by one or more groups, which may be identical or different, selected from

[0051] i)-O-R3;

[0052] ii) -S-R3;

[0053] iii) -C(O)-O-R3 ;

[0054] iv) an aryl group in C5-Ci2, optionally substituted by one or more hydroxyl groups and / or by one or more alkoxy radicals in Ci-C8 and

[0055] c) an aryl group in C5-Ci2, optionally substituted by one or more hydroxyls and / or with one or more alkoxy radicals in CrC8;

[0056] - R 3 designates a radical chosen from:

[0057] a) a hydrogen atom and

[0058] b) a linear saturated alkyl group in Ci-Cio or branched in C3-CiO;

[0059] ii) at least one reducing agent of formula (II) its mesomeric forms and its solvates such as hydrates

[0060] [Chem.2] O .......S.........O kl pL (II)

[0061] in which,

[0062] X represents a heteroatom chosen from oxygen or sulfur, preferably oxygen;

[0063] m is equal to 0 or 1;

[0064] M+ is a cation, preferably chosen from an alkali metal, an alkaline earth metal or an ammonium, more preferably chosen from an alkali metal such as sodium or potassium;

[0065] R represents a group chosen from:

[0066] i) -OH,

[0067] ii) -O-M'+ with M'+ as defined previously for M+,

[0068] iii) o in which, f H

[0069] • p is an inclusive integer chosen between 0 and 4, preferably 0, 1, 2 and more preferably 0 or 2;

[0070] • m' is worth 0 or 1, preferably 1;

[0071] • X' is such that defined for X, preferably X' represents an oxygen atom; and

[0072] • M' '+ is such as defined previously for M+, and M+, M'+, M' '+ are identical or different, preferably identical;

[0073] and

[0074] iii) of arginine, on keratinous material, preferably skin.

[0075] Another aspect of the present invention proposes a use of the composition comprising:

[0076] i) at least one compound selected from a compound of formula (I) below, its tautomer of formula (!') below, their salts, solvates, hydrates, optical isomers, racemates or mixtures thereof: O JL, .¾ he . X - Ri O 1 Rj aaa 'N ' M ii si V . Ri N'" S 1 ? H Formula (I) Formula (I')

[0077] in which,

[0078] - R i designates a radical chosen from:

[0079] a) a hydrogen atom;

[0080] b) a linear saturated alkyl group in the form of Ci-Cio or branched in the form of C3-CiO optionally substituted by one or more groups, which may be identical or different, selected from:

[0081] i)-O-R3 ; and

[0082] ii) -S-R3;

[0083] - R 2 denotes a radical chosen from:

[0084] a) a hydrogen atom;

[0085] b) a linear saturated CrCi2 hydrocarbon group or a C3-Ci2 branched hydrocarbon group or a C3-C8 cyclic hydrocarbon group, optionally substituted by one or more groups, which may be identical or different, selected from

[0086] i) -O-R3;

[0087] ii) -S-R3;

[0088] iii) -C(O)-O-R3 ;

[0089] iv) an aryl group at C5-Ci2, optionally substituted by one or more hydroxyl groups and / or by one or more alkoxy radicals in CrC8 and

[0090] c) an aryl group in C5-Ci2, optionally substituted by one or more hydroxyls and / or with one or more alkoxy radicals in CrC8;

[0091] - R 3 designates a radical chosen from:

[0092] a) a hydrogen atom and

[0093] b) a linear saturated alkyl group in Ci-Cio or branched in C3-CiO;

[0094] ii) at least one reducing agent of formula (II) its mesomeric forms and its solvates such as hydrates

[0095] [Chem.3] O R---S--O" M + (II)

[0096] in which,

[0097] X represents a heteroatom chosen from oxygen or sulfur, preferably oxygen;

[0098] m is equal to 0 or 1;

[0099] M+ is a cation, preferably chosen from an alkali metal, an alkaline earth metal or an ammonium, more preferably chosen from an alkali metal such as sodium or potassium;

[0100] R represents a group chosen from:

[0101] i) -OH,

[0102] H) -O-M'+ with M'+ as defined previously for M+,

[0103] iii) in which, —fS]—SO" M” ' ' He 1¾

[0104] • p is an inclusive integer chosen between 0 and 4, preferably 0, 1, 2 and more preferably 0 or 2;

[0105] • m' is worth 0 or 1, preferably 1;

[0106] • X' is such that defined for X, preferably X' represents an oxygen atom; and

[0107] -M”+ is such as defined previously for M+, and M+, M'+, M”+ are identical or different, preferably identical;

[0108] and

[0109] iii) arginine, for lightening or depigmenting keratinous material, preferably skin.

[0110] Another aspect of the present invention proposes the use of a combination of

[0111] (i) at least one reducing agent of formula (II), its mesomeric forms and its solvates such as hydrates

[0112] [Chem.4] O ___g___q" fyp (ii)

[0113] in which,

[0114] X represents a heteroatom chosen from oxygen or sulfur, preferably oxygen;

[0115] m is equal to 0 or 1;

[0116] M+ is a cation, preferably chosen from an alkali metal, an alkaline earth metal or an ammonium, more preferably chosen from an alkali metal such as sodium or potassium;

[0117] R represents a group chosen from:

[0118] i)-OH,

[0119] ü) -O-M'+ with M'+ as defined previously for M+,

[0120] iii) 0 in which, —[S]—S--O ' M"' ? he [k jra'

[0121] • p is an inclusive integer chosen between 0 and 4, preferably 0, 1, 2 and more preferably 0 or 2;

[0122] • m' is worth 0 or 1, preferably 1;

[0123] • X' is such that defined for X, preferably X' represents an oxygen atom; and

[0124] • M' '+ is such as defined previously for M+, and M+, M'+, M”+ are identical or different, preferably identical and

[0125] (ii) of arginine,

[0126] in a composition comprising at least one compound selected from the compounds of formula (I), its tautomer of formula (!'), their salts, optical isomers, racemates, solvates, hydrates, or mixtures thereof: OHO 1 he A . r^ W' 'g H Formula (I) Formula (I')

[0127] formulas (I) and (I') in which:

[0128] - R i designates a radical chosen from:

[0129] a) a hydrogen atom;

[0130] b) a linear saturated alkyl group in the form of Ci-Cio or branched in the form of C3-CiO optionally substituted by one or more groups, which may be identical or different, selected from:

[0131] i)-O-R3 ; and

[0132] ii) -S-R3;

[0133] - R 2 denotes a radical chosen from:

[0134] a) a hydrogen atom;

[0135] b) a linear saturated CrCi2 or C3-Ci2 branched or C3-C8 cyclic hydrocarbon group, optionally substituted by one or more groups, which may be identical or different, selected from:

[0136] i) -O-R3;

[0137] ii) -S-R3;

[0138] iii) -C(O)-O-R3 ;

[0139] iv) an aryl group at C5-Ci2, optionally substituted by one or more hydroxyls and / or by one or more alkoxy radicals in Ci-C8;

[0140] c) an aryl group in C5-Ci2, optionally substituted by one or more hydroxyl groups and / or by one or more CrC8 alkoxy radicals; and

[0141] - R 3 designates a radical chosen from:

[0142] a) a hydrogen atom;

[0143] b) a linear saturated alkyl group in Ci-Cio or branched in C3-CiO,

[0144] to stabilize the compound of formula (I), its tautomer of formula (!'), their salts, solvates, hydrates, optical isomers, racemates or mixtures thereof, in the composition.

[0145] These features, aspects, and advantages, as well as others, of the present subject matter will be better understood with reference to the following description and the attached claims. The purpose of this summary is to present a selection of concepts in a simplified form. This summary is not intended to identify key features or essential features of the claimed subject matter, nor to be used to limit the scope of the claimed subject matter. DESCRIPTION OF THE INVENTION

[0146] Those skilled in the art will be aware that this disclosure is subject to variations and modifications other than those specifically described. It should be understood that this disclosure includes all such variations and modifications. The disclosure also includes all such steps, features, compositions, and compounds designated or indicated in this patent memorandum, individually or collectively, and any combination of one or more of these steps or features.

[0147] Definitions

[0148] For convenience, before describing this disclosure in more detail, certain terms used in the patent memorandum and examples are defined here. These definitions should be read in light of the rest of the disclosure and understood as by a person skilled in the art. The terms used here have meanings recognized and known to a person skilled in the art; however, for convenience and completeness, particular terms and their meanings are set out below.

[0149] The terms “include” and “comprising” are used in an inclusive and open sense, meaning that additional elements may be included. They are not intended to be interpreted as “consists solely of”.

[0150] The expression "at least one" is used to mean one or more and therefore includes individual components as well as mixtures / combinations.

[0151] Throughout this patent brief, unless the context otherwise requires, the term "include", and variations such as "includes" and "comprising", shall be understood to imply the inclusion of any element or step or group of elements or steps stated, but not the exclusion of any other element or step or group of elements or steps.

[0152] The term "including" is used to mean "including, but not limited to". "Including" and "including, but not limited to" are used interchangeably.

[0153] The term "INCI" is an abbreviation for International Nomenclature of Cosmetic Ingredients, which is a system of names provided by the International Nomenclature Committee of the Personal Care Products Council to describe the ingredients of personal care products.

[0154] All percentages, parts, and ratios are based on the total weight of the compositions in this disclosure, unless otherwise stated. Ratios, concentrations, quantities, and other numerical data may be presented herein in a range format. It should be understood that this range format is used solely for convenience and conciseness and should be interpreted flexibly as including not only the numerical values ​​explicitly cited as the range limits, but also as including all individual numerical values ​​or subranges encompassed within that range as if each numerical value and subrange were explicitly cited.For example, a percentage range by weight of about 0.01% to 10% should be interpreted as including not only the explicitly quoted limits of about 0.01% to about 10%, but also as including sub-ranges, such as 0.02% to 0.05%, 1% to 10%, and so on, as well as individual quantities, including fractional quantities, within the specified ranges, such as 1.5%, 5.3% and 9.25%, for example.

[0155] For the purposes of this disclosure, and unless otherwise indicated:

[0156] a) a "linear CrCi2 or C3-Ci2 branched saturated hydrocarbon group" is equivalent to a "linear (C1-C12) or branched (C3-C12) alkyl group" which corresponds to a linear C1-C12 or C3-C12 branched saturated hydrocarbon group, and preferably to a linear C1-C10 or C3-C10 branched hydrocarbon group, more preferably to a linear Ci-C6 or C3-C6 branched hydrocarbon group; preferably, the linear or branched groups may be selected from the methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl groups. More preferably, the linear or branched saturated alkyl groups can be chosen from the methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl, pentyl, hexyl, heptyl and octyl groups, such as methyl, ethyl, n-pentyl, n-nonyl, isobutyl;

[0157] b) a saturated hydrocarbon group "C3-C8 cyclic" is a mono- or bicyclic cycloalkyl group containing 3 to 8 carbon atoms and, in particular, is a monocyclic cycloalkyl group having C5 to C7 atoms, such as a cyclohexyl group,

[0158] c) an "alkoxy radical" is an alkyl-oxy radical for which the alkyl radical is a linear or CrCi6 branched hydrocarbon radical and, preferably, a CrC8 branched hydrocarbon radical; where the alkoxy group is optionally substituted, this implies that the alkyl group is optionally substituted as defined herein;

[0159] (d) an “aryl” group means a carbon-based group, monocyclic or bicyclic, fused or unfused, comprising from 5 to 12 carbon atoms, preferably from 6 to 10 carbon atoms, and in which at least one ring is aromatic; preferably, the aryl radical is a phenyl, a biphenyl, a naphthyl, more preferably a phenyl group;

[0160] e) the expression "at least one" is equivalent to the expression "one or more"; and

[0161] f) the term "included" for a concentration range means that the limits of that range are included in the defined range.

[0162] The salts of compounds of formula (I), (!'), (la) or (la') include conventional non-toxic salts of said compounds, such as those formed from an organic or inorganic acid or an organic or inorganic base.

[0163] As salts of compounds of formula (I), (!'), (la) or (la1), we may mention: the salts obtained by adding the compound of formula (I) to

[0164] i) a mineral base, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, ammonium hydroxide, magnesium hydroxide, lithium hydroxide, and sodium, potassium or calcium carbonate or hydrogen carbonate, for example; or

[0165] ii) an organic base such as a primary, secondary or tertiary alkylamine, for example a triethylamine or butylamine. This primary, secondary or tertiary alkylamine may comprise one or more nitrogen and / or oxygen atoms and may therefore comprise, for example, one or more alcohol functions; examples include 2-amino-2-methylpropanol, ethanolamine, triethanolamine, 2-dimethylaminopropanol, 2-amino-2-(hydroxymethyl)-1,3-propanediol and 3-(dimethylamino)propylamine.

[0166] Other examples include amino acid salts, for instance lysine, arginine, guanidine, glutamic acid, and aspartic acid. Advantageously, the salts of compounds of formula (I) (when they include a carboxy group) can be selected from alkali metal or alkaline earth metal salts such as sodium, potassium, calcium, or magnesium salts and ammonium salts.

[0167] A "salt of an organic or inorganic acid" is more particularly chosen from salts chosen from a salt derived from i) hydrochloric acid HCl, ii) hydrobromic acid HBr, iii) sulfuric acid H2SO4, iv) alkylsulfonic acids: Alk-S(O)2OH such as methanesulfonic acid and ethanesulfonic acid; v) arylsulfonic acids: Ar-S(O)2OH such as benzenesulfonic acid and toluenesulfonic acid; vi) citric acid; vii) succinic acid; viii) tartaric acid; ix) lactic acid; x) alkoxysulfinic acids: Alk-OS(O)OH such as methoxysulfinic acid and ethoxysulfinic acid; xi) aryloxysulfinic acids such as tolueneoxysulfinic acid and phenoxysulfinic acid; xii) acid phosphoric acid H3PO4; xiü) acetic acid CH3C(O)OH; xiv) triflic acid CF3SO3 H; and xv) tetrafluoroboric acid HBF4.

[0168] Acceptable solvates of the compounds described in the patent memorandum include conventional solvates such as those formed during the preparation of said compounds due to the presence of solvents. Examples include solvates due to the presence of water or linear or branched alcohols, such as ethanol or isopropanol.

[0169] Optical isomers of formula (I) or (!') are, in particular, enantiomers and diastereomers.

[0170] Mesomeric forms of formula (II) represent isomers of compounds of formula (II) resulting from the delocalization of electrons around heteroatoms such as oxygen and / or sulfur.

[0171] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those commonly accepted by a person skilled in the art of this disclosure. Although all processes and materials similar or equivalent to those described herein may be used in the practice or testing of the disclosure, preferred processes and materials are hereby described.

[0172] This disclosure shall not be limited in scope by the specific embodiments described herein, which are intended for illustrative purposes only. Functionally equivalent products, compositions, and processes clearly fall within the scope of the disclosure as described herein. Composition

[0173] The present invention provides a composition, preferably a cosmetic composition comprising at least one compound corresponding to the following formula (I) or (I'), referred to as a "thiopyridinone-type compound" or "thiopyridinone compound." It may be preferable for the present invention to provide cosmetic compositions comprising a combination of a thiopyridinone-type compound (I) or (F) with at least one reducing agent of formula (II) and arginine, which exhibits increased stabilization, in particular improved photostability, of the thiopyridinone compounds and of the cosmetic composition comprising them. The present invention provides methods for improving the stability of thiopyridinone-type compounds (I) or (F) in cosmetic compositions that are useful for treating keratinous material, for example, the skin of the face and neck of a human.The "stability" of the thiopyridinone compound can be determined by changing the amount of thiopyridinone in the composition according to the present invention over a certain period of time. The "photostability" of the thiopyridinone compound can also be determined by changing the amount of thiopyridinone. in the composition according to the present invention after exposure to light. Increased "stability" or "photostability" means that the variation in the amount of the thiopyridinone compound over time is more limited, particularly after exposure to light of the composition comprising the thiopyridinone compound.

[0174] The present invention also provides non-therapeutic methods for treating skin, including applying the cosmetic composition of the present invention to the skin to impart a lightening or whitening effect. The cosmetic compositions are also useful in non-therapeutic methods for treating brown spots and uneven skin texture. Thiopyridinone compound

[0175] According to one embodiment, the present invention provides a composition, preferably a cosmetic composition comprising:

[0176] I. at least one compound selected from a compound of formula (I) below, its tautomer of formula (!') below, their salts, solvates, hydrates, optical isomers, racemates or mixtures thereof: O Il l 4 1 HOX ii tw SJH Formula (I) Formula (I')

[0177] in which,

[0178] - R i designates a radical chosen from:

[0179] a) a hydrogen atom; and

[0180] b) a linear saturated alkyl group in the form of Ci-Cio or branched in the form of C3-CiO optionally substituted by one or more groups, which may be identical or different, selected from:

[0181] i)-O-R3;

[0182] ii) -S-R3;

[0183] - R 2 denotes a radical chosen from:

[0184] a) a hydrogen atom;

[0185] b) a linear saturated hydrocarbon group in C1-C12 or branched in C3-C12 or cyclic in C3-C8, optionally substituted by one or more groups, which may be identical or different, selected from

[0186] i) -O-R3;

[0187] ii) -S-R3;

[0188] iii) -C(O)-O-R3 ;

[0189] iv) an aryl group in C5-Ci2, optionally substituted by one or more hydroxyl groups and / or by one or more CrC8 alkoxy radicals and

[0190] c) an aryl group in C5-Ci2, optionally substituted by one or more hydroxyls and / or with one or more alkoxy radicals in CrC8;

[0191] - R 3 designates a radical chosen from:

[0192] a) a hydrogen atom and

[0193] b) a linear saturated alkyl group in Ci-Cio or branched in C3-C10;

[0194] II. at least one reducing agent of formula (II), its mesomeric forms and its solvates such as hydrates

[0195] [Chem.5] O R--S--O~M* P <k (II)

[0196] in which

[0197] X represents a heteroatom chosen from oxygen or sulfur, preferably oxygen;

[0198] m is equal to 0 or 1;

[0199] M+ is a cation, preferably chosen from an alkali metal, an alkaline earth metal or an ammonium, more preferably chosen from an alkali metal such as sodium or potassium;

[0200] Represents a group chosen from:

[0201] i) -OH,

[0202] H) -O-M'+ with M'+ as defined previously for M+,

[0203] iii) in which, __L | o M [Xk

[0204] • p is an inclusive integer chosen between 0 and 4, preferably 0, 1, 2 and more preferably 0 or 2;

[0205] • m' is worth 0 or 1, preferably 1;

[0206] • X' is such that defined for X, preferably X' represents an oxygen atom; and

[0207] • M' '+ is such as defined previously for M+, and M+, M'+, M' '+ are identical or different, preferably identical;

[0208] and

[0209] III. of arginine.

[0210] The compounds used according to the present invention therefore correspond to the formula (I) or the tautomer (!') below or to their salts, their optical isomers, racemates, and / or solvates such as hydrates, alone or in mixture. 0 (I) (D

[0211] formulas (I) and (!') in which:

[0212] Ri designates a radical chosen from:

[0213] a) a hydrogen atom;

[0214] b) a linear saturated alkyl group in C1-C10 or branched in C3-C10 optionally substituted by one or more groups, which may be identical or different, selected from:

[0215] i) -O-R3

[0216] ii) -S-R3;

[0217] R2 denotes a radical chosen from:

[0218] a) a hydrogen atom;

[0219] b) a linear saturated CrCi2 or C3-Ci2 branched or C3-C8 cyclic hydrocarbon group, optionally substituted by one or more groups, which may be identical or different, selected from:

[0220] i) -O-R3;

[0221] ii) -S-R3;

[0222] iii) -C(O)-O-R3 ;

[0223] iv) an aryl group at C5-Ci2, optionally substituted by one or more hydroxyl groups and / or one or more alkoxy radicals in the C1-C8 group; and

[0224] c) an aryl group in C5-Ci2, optionally substituted by one or more hydroxyl groups and / or by one or more CrC8 alkoxy radicals

[0225] in which

[0226] R3 designates a radical chosen from:

[0227] a) a hydrogen atom; and

[0228] b) a linear saturated alkyl group in Ci-Cio or branched in C3-Ci0.

[0229] The compound (!') is the tautomeric form of compound (I) when an equilibrium tautomeric exists according to the following scheme:

[0230] According to one embodiment of the invention, Ri represents a hydrogen atom.

[0231] According to another embodiment of the invention, Ri represents a linear (Ci-Ci) alkyl group or a branched (C3-C10) alkyl group, in particular a linear (Ci-C6) or branched (C3-C6) alkyl group, such as methyl, ethyl, n-pentyl, n-nonyl, isobutyl, more preferably ethyl. In particular, said alkyl group of Ri is unsubstituted.

[0232] According to one embodiment of the invention, R2 represents a hydrogen atom.

[0233] According to another embodiment of the invention, R2 represents a linear (C1-C10) alkyl group or a branched (C3-C10) alkyl group, in particular a linear (C1-C6) or branched (C3-C6) alkyl group, such as methyl, ethyl, n-pentyl, n-nonyl, isobutyl, more preferably a methyl or ethyl group; said alkyl group of R2 not being substituted.

[0234] According to another embodiment of the invention, R2 represents a linear (C1-C10) or branched (C3-C10) alkyl group, in particular a linear (C1-C6) or branched (C3-C6) alkyl group, such as methyl, ethyl, n-pentyl, n-nonyl, isobutyl, more preferably methyl or ethyl; said alkyl group being substituted by one or more groups selected from i), ii), iii) and iv) as defined above. Preferably, said alkyl group is substituted by one or two groups selected from i), ii) and iii), more preferably by one or two groups selected from i) and iii), or better yet, substituted by a group iii) such as a carboxy.

[0235] Another variant for the radical R2 is that said alkyl group is substituted by a group iv) in particular substituted by a phenyl group.

[0236] According to another embodiment of the invention, R2 represents a cycloalkyl group (in C3-C8), preferably a cycloalkyl group (in C5-C7) such as cyclohexyl.

[0237] According to another embodiment of the invention, R2 represents an aryl group in C5 Ci2 optionally substituted by one or more hydroxyls and / or by one or more alkoxy radicals in CrC8 preferably a phenyl group in particular unsubstituted.

[0238] According to one embodiment, R3 represents a hydrogen atom.

[0239] According to another embodiment, R3 represents a saturated linear Ci-Cio or branched C3-C10 alkyl group; in particular a linear (Ci-C6) alkyl group or a branched (C3-C6) alkyl group, preferably an (CrC4) alkyl group such as the methyl group.

[0240] Preferably, the compounds of formula (I) and the tautomer (!') or their salts, their optical isomers, racemates, and / or solvates such as hydrates and their derivatives, alone or in mixture;

[0241] have the following meanings:

[0242] Ri designates a radical chosen from:

[0243] a) a hydrogen atom;

[0244] b) a linear saturated alkyl group in C1-C6 or branched in C3-C6 optionally substituted by one or more groups, which may be identical or different, selected from:

[0245] i) -O-R3;

[0246] ii) -S-R3;

[0247] preferably optionally substituted by one or more groups i);

[0248] R2 denotes a radical chosen from:

[0249] a) a hydrogen atom;

[0250] b) a linear saturated hydrocarbon group in C1-C10 or branched in C3-C10 or cyclic in C3-C8 as in C5-C6, optionally substituted by one or more groups, which may be identical or different, selected from:

[0251] i)-O-R3;

[0252] ii) -SR3;

[0253] iii) -C(O)-O-R3 ;

[0254] iv) a phenyl group optionally substituted by one or more hydroxyl groups and / or by one or more C1-C4 alkoxy radicals such as a methoxy;

[0255] preferably substituted by one or more groups selected from i) and iii), preferably iii) such that carboxy

[0256] R3 designates a radical chosen from:

[0257] a) a hydrogen atom;

[0258] b) a linear saturated alkyl group in Ci-C6 or branched in C3-C6.

[0259] Preferably, the compounds of formula (I) and the tautomer (!') or their salts, their optical isomers, racemates, and / or solvates such as hydrates and their, alone or in mixture, have the following meanings:

[0260] Ri designates a radical chosen from:

[0261] a) a hydrogen atom;

[0262] b) a linear saturated alkyl group in C1-C4 or branched in C3-C4 optionally substituted by one or more groups, which may be identical or different, chosen from i) -OR3jplus preferably unsubstituted;

[0263] R2 denotes a radical chosen from:

[0264] a) a hydrogen atom;

[0265] b) a linear saturated hydrocarbon group in C1-C10 or branched in C3-C10 or cyclic in C3-C8 as in C5-C6, optionally substituted by one or more groups, which may be identical or different, selected from:

[0266] i. -O-R3 ;

[0267] ii. -C(O)-O-R3 ;

[0268] iv. an aryl group in C5-Ci2, optionally substituted by one or more hydroxyls and / or by one or more alkoxy radicals in Ci-C4;

[0269] R3 designates a radical chosen from:

[0270] a) a hydrogen atom;

[0271] b) a linear CrC4 saturated alkyl group or a C3-C4 branched alkyl group such as a methyl or an ethyl.

[0272] Preferably, the compounds of formula (I) and the tautomer (P) or their salts, their optical isomers, racemates, and / or solvates such as hydrates and their derivatives, alone or in mixture;

[0273] have the following meanings:

[0274] Ri is a hydrogen atom; and

[0275] R2 denotes a radical chosen from:

[0276] a) a hydrogen atom;

[0277] b) a linear saturated hydrocarbon group in C1-C5 or branched in C3-C5 or cyclic in C3-C8 such as in C5-C6, substituted by one or more groups, which may be identical or different, selected from v) —C(O)-O-R3, preferably substituted by a group iii) —C(O)-O-R3 and

[0278] R2 is even more preferably a linear saturated CrC4 hydrocarbon group or a C3-C4 branched group substituted by a iii) -C(O)-OR3 group, and

[0279] R3 designates a radical chosen from:

[0280] a) a hydrogen atom;

[0281] b) a linear CrC4 saturated alkyl group or a C3-C4 branched alkyl group such as a methyl or an ethyl.

[0282] According to another preferred embodiment, the compounds of formula (I) and the tautomer (!') are chosen from the compounds of formula (la) and also their tautomers of formula (la') below, their salts, their solvates and their optical isomers, and their racemates, alone or in mixture: O .11 X c pY 'FY %As h, ü H 0 rykT

[0283] In formulas (la) and (la'), Ri and R3 have the same meaning as for compounds of formula (I) and (!') and X denotes an alkylene radical -(CH2)n-, n being an integer from 1 to 10 inclusive, preferably from 1 to 6, more preferably from 1 to 4, such that 1, preferably R3 represents a hydrogen atom.

[0284] Among the compounds of formula (I), the following compounds are preferably used, and their tautomer or their salts, their optical isomers, racemates, and / or solvates such as hydrates and their derivatives, alone or in mixtures: N" Structure Chemical name ir cas 1 1 ZX 'Z 0 x A Yr'" H N-éthyk24hloxo- 1.2-djhydrapyndine- S-carhoxamsde 91859-75-5 2 / Y........Z \ / -3⁄4 V- s; N -méthybS-thjoxa-1.2-dihydropyddîRe-3-carboxamide 91859-74-4 3 ri Y ¥..... N-octyl-2-thioxo- 1,2 -dih vdî c pyndine-3-cart)oxamid.é 91-774-7.7 1 f Y v Ti ¥„ Y..- ■Y»-'' N-benzyf-2-thioxo-1 ,,2-dW dwTidine-3-carboxafmde 91859-79-9 .5 _ Y % z: V / K / ™%, «K---—VX Y- Z N-phenyl-2-tbsoxQr 1 YdtftydropYdd^ 3-carboxamaie 104857-16-1 G z" x-?r'" HU f' "-2 Y-XOW-K -K 1 ^-dihydropysldine- 3-e.arboxanmde 91859-78-8 7 ZY'“ n? xy N- [2 -( 4 -metîoxy phény i J èiUY>-24h©xo-1,2-dihydropyndinfr-3-carboxamkle 923682-88-6 8 rY" Y OK, 1 IL i 1 ÏT '■“ :$Qfié N-2(2 ,.2-dihydmpyddine- 3-carboxam^e 1100027-79-9 9 ex * YH 'SX^X'v"-- ■H $ N-pentyl-2-îhfoxo-1,2-dihy ôropyndine-3-carboxamjde-350676 10 ' N-nonyl5-24hioxo- 1 J-^hydrGpyndsne- 3-€ari3üxafï»de W31149-44-S 11 ( 'T N-(2-hydrox / éthyrj- 2-thiü1 Nïxo- 1 ,.2-dihydropyÈ2carid^e-2 ,.2-dihydropyÈ2carid^e-2 ^n&rcaptonicofeamidé 13 ..-s .ff ^y'"" " "N-------... ;. pr&pyl)-2-îhæxc- 1 J-dîhÿdrGpyddhe-l-cas'boxamMe 15 N-( 1 ...3-dîhy drûxypr^^ 2-y|)^4hfoxo-1 ,.2-dihydropyfid^&-3-carboxamïà w & CHS / '<v k- 'S.v' IM-[Mœæ- 1 2-dshyC'F'jpy^Lhfi-3-y I !£&$0¾ U déthylê N i s / y > y tW 17 0 ■' F N-[Q-th©vo- 1 Z-dîhy^r^pyndsn- 3-ylbsaÆ^IJn^^^^ d èthyie 18 [ ,, i „ tti ;< — 1- Î4-H2-WOXO-1 2-dsli>Gfu^®n-3-jl^o^ttLâ^ dé^J- W 1 F: F ..zx., ■$ <■: N-[Q-îhFQKS-t2-dshyG'i □pyndsn-3-ÿh^h^J]^yQn^ d éthyle 20 i .« LT v ï !* N-K2-Wœ®-V-dihydrapyndiEv S-yHegïtayllWc^ 21 L w !-S 1,2^ÿ£topÿrâfiR-3-yDotaWg^^ 22 T i . IY ""' $• •-> 2 <rô©- i 2-dshy^rapyhdm«- 3-cætoiæwte 23 n » Mt. A, . <y Y Y - - ■ :-y N-(3-mêihoxÿpropy0-2-t^i®®- 12-dihy(kopyÉdme- 3-cartaamde 24 n .. e-x £*• Y' Y s ^f2-8ïiw 1,2-d^hydrapy^ne-3-cadx»?amde'

[0285] With these components, the components that contain the most advanced parts: NSCAS 1 or Yx. [1 1 " K. N-éttyI-2-thiœ<o-1,2-dshy^rapy^ne-3-eaïtatamide 9i859-75-5 2 Y Y Z Y > """'< \ YY Y. - Y N-meWIY-th^KS- 1 3-cattoKamide 91859-74-4 4 \Z -Y Nt-nzx KYhaxû-1,2-dthy Prapvnd?ne-S-cadxeaRM', 91 Y859 y79 y79aRM', 91 Y859 y79 N-cydQh£vy^Y4W <o-12-®ydrûp;tsdsri&-3*carfe&xamsde 91859-78-8 Chemical Mo® structure N* CA S 7 [. is N- [2-i4-method. <y értÿt) 12-dstyGropyrKfene- 3-carbOAamscte 9236S2-SS-6 9 X : X^S-. N-pentjO4;hfflXG-12-® y topyndme-3-cadwamefe 330^-7-57-7 11 V H N-Œ^&oxyéthyO- 2-I^îgxü- 1.2-dshydropyncfne- 3-caïbûxamjde 12 h h l 2-n> ef ?aptOTC0§ftarr|de 14 ,. <x>v' i'5-: >f'' N-(2 3-dihYdrœtyprspyO-2-^iûxd- 1,2-dshydro^Ticfr®- 3-£aft?ox3msde 15 H H-(1 J-dWdro>W®PSR- 2-yi>2-fiiûXQ- 12-dshyqropyddme- 3-carbQxamsde 16 » 0¾ rY'vV Y % ", y. H:C N-[.2-tho> ^-12-dthxdrcpv^dfci-3-' 1 d ethnicity 17. 9 CX y! "iY 5W<ww-V-dshvdropÿrèfe-3-yl d etiwle 19 ...> x » / / . H.....Y ' YV: '■■-Y""' << N-[J 2-tM<0- ' 2-d*h\tlrcpvncfa- d eYyle 20 Y f T r 1 x ,4?xc' Yy ■ ■ NH(24htax.G- 3-ylYafà 21 A i '[ i T ■ ..K, m, an K H-meSiyl-fH(2-W®o-1 3-yf^feœWcine

[0286] More preferably, among these compounds, the following compounds are more particularly preferred: Ne Structure Name cïifeniqae ir case s) N-ê^kZ-tWxQ-12-® ^rap^îrâfoe- S1S59-75-5 1 P Y'"" Px:i? ! H 3-csd»xamscfe H XxP & ! ..... SP Xs..< X Np«nM-2-t1W'O- 1 ^-«Shyckopyn^ne-3-Œtoamsde 330667-57-7 16 >• Ss CH i. 1 J . r 'S 0 HC N-hJ-t^iO' 3- ! ^AlhysJtopyôdm- d eihvle 18 c - K "'•y \ •Û^î -, 1,2-®ydrapy^^ d'êlhyfe 19 Pl .À .. >. .<■.!:. ' v Y N-[(2-Wo- 1.2-®!^^Mî>Mî>Mî^Mî^) drê^te P, ,.x -'i 20 c P»'^sZ" JH N-[(2-feiœ«.a-12-dshytopyr^ 3-yliXaÆWl^^ne ï-r "P'ÿ & PV N-meîhvl4H(2-»Xû- 12-chhvdropyndy^n-3 <U^^ 21 ■ !-$ sM OH ■^s

[0287] Still more preferentially, among these compounds, the following compounds are more particularly preferred: H3 Name: chemical 1T CASE 18 rf H ! d'ê^yle 19 ) Z x / ■ " y...... / / y. \_________ / N-[(2-thiox&-1,2-dihÿdropyndsh- d'éWte 20 CX v ï 12-dihydropyddm- 3-yQcafàwc^ 21 (xy y 1,2-dihÿdropynds-n

[0288] In a preferred embodiment, the compound according to the present The invention is as follows: 20A. KHQ-thsoxs-1;2-dihydrspyddm-

[0289] All the above compounds can be obtained by a chemical process known to those skilled in the art, from commercially available reagents.

[0290] The (1) thiopyridinone compound of formula (I) or (I1) can be prepared according to the process described, for example, in EP-A-3 390 363 or WO 2017 / 102349.

[0291] The (1) thiopyridinone compound may be an active ingredient or active compound in cosmetic or dermatological products. The term "active ingredient" or "active compound" used herein refers to an ingredient or compound that has an active cosmetic or dermatological property, such as antioxidant, bleaching, UV-filtering, and antibacterial effects. The (1) thiopyridinone compound used in the present invention may function as a depigmenting, lightening, bleaching, or whitening agent, and thus the composition according to the present invention may be used as a lightening product or as a cosmetic composition for lightening keratinous material.

[0292] The (1) thiopyridinone compound may be used as an agent for depigmenting, lightening, bleaching or whitening the skin, body hair, eyelashes or hair, and also the lips and / or nails, and preferably the skin, in particular for removing pigmentation spots or age spots and / or as an anti-tanning agent.

[0293] According to one embodiment of the present invention, the amount of the (1) thiopyridinone compound(s) in the composition may be 0.01% by weight or more, preferably 0.05% by weight or more and, more preferably, 0.1% by weight or more, relative to the total weight of the composition.

[0294] According to one embodiment of the present invention, the amount of the (1) thiopyridinone compound(s) in the composition may be 10% by weight or less, preferably 5% by weight or less, and more preferably 3% by weight or less, relative to the total weight of the composition.

[0295] According to one embodiment of the present invention, the quantity of the (1) thiopyridinone compound(s) in the composition according to the present invention can range from 0.01% to 10% by weight, preferably from 0.05% to 5% by weight, and more preferably from 0.1% to 3% by weight, relative to the total weight of the composition.

[0296] According to another embodiment of the present invention, the quantity of the (1) thiopyridinone compound(s) in the composition can range from 0.01% to 10% by weight, preferably from 0.1% to 5% by weight, and more preferably from 0.5% to 3% by weight, relative to the total weight of the composition.

[0297] The composition according to the present invention comprises (1) at least one thiopyridinone compound. Two (1) or more thiopyridinone compounds may be used in combination. Thus, only one type of (1) thiopyridinone compound or a combination of different types of (1) thiopyridinone compounds may be used.

[0298] The (1) thiopyridinone compound is selected from the compounds of formula (I) below, the tautomers of formula (!') below, their salts, their solvates, such as their hydrates, their optical isomers, their racemates and mixtures thereof: O.....x Rs y...x. HO a < N' Ri NS ' 1 H (I) (D

[0299] formulas (I) and (!') in which:

[0300] Ri designates a radical chosen from:

[0301] a) a hydrogen atom;

[0302] b) a linear saturated alkyl group in C1-C10 or branched in C3-C10 optionally substituted by one or more groups, which may be identical or different, selected from:

[0303] i) -O-R3;

[0304] ii) -S-R3;

[0305] R2 denotes a radical chosen from:

[0306] a) a hydrogen atom;

[0307] b) a linear saturated CrCi2 or C3-Ci2 branched or C3-C8 cyclic hydrocarbon group, optionally substituted by one or more groups, which may be identical or different, selected from:

[0308] i. -O-R3 ;

[0309] ii. -S-R3;

[0310] iii. -C(O)-O-R3 ;

[0311] iv. an aryl group at C5-Ci2, optionally substituted by one or more hydroxyl groups and / or one or more CrC8 alkoxy radicals; and

[0312] c) an aryl group in C5-Ci2, optionally substituted by one or more hydroxyl groups and / or by one or more CrC8 alkoxy radicals

[0313] in which

[0314] R3 designates a radical chosen from:

[0315] a) a hydrogen atom; and

[0316] b) a linear saturated alkyl group in Ci-Cio or branched in C3-Ci0. Reducing agent

[0317] According to one embodiment of the present invention, the composition comprises at least one (2) reducing agent of formula (II), its mesomeric forms, and its solvates such as hydrates O (II) rxi

[0318] in which

[0319] X represents a heteroatom selected from oxygen or sulfur, preferably oxygen;

[0320] m is equal to 0 or 1;

[0321] M+ is a cation, preferably chosen from an alkali metal, an alkaline earth metal or an ammonium, more preferably chosen from an alkali metal such as sodium or potassium;

[0322] Represents a group chosen from:

[0323] i) -OH,

[0324] ü) -O-M'+ with M'+ as defined previously for M+,

[0325] iii) Q in which,

[0326] • p is an inclusive integer chosen between 0 and 4, preferably 0, 1, 2 and more preferably 0 or 2;

[0327] • m' is worth 0 or 1, preferably 1;

[0328] • X' is such that defined for X, preferably X' represents an oxygen atom; and

[0329] • M' '+ is such as defined previously for M+, and M+, M'+, M' '+ are identical or different, preferably identical.

[0330] According to another embodiment of the present invention, the composition comprises at least one (2) reducing agent of formula (II) in which

[0331] X of formula (II) represents a heteroatom chosen from oxygen or sulfur, preferably oxygen;

[0332] m of formula (II) is equal to 0 or 1;

[0333] M+ of formula (II) is a cation, preferably sodium or potassium;

[0334] R of formula (II) represents a group chosen from

[0335] i) -OH,

[0336] ü) -O-M'+ with M'+ as defined previously for M+,

[0337] iii) in which,

[0338] • p is equal to 0 or 2;

[0339] •m' is worth 0 or 1;

[0340] • X' is such that defined for X, preferably X' represents an oxygen atom; and

[0341] M+, M'+, M”+ are identical.

[0342] According to one embodiment of the present invention, wherein in the (2) reducing agent of formula (II)

[0343] R represents a group chosen from:

[0344] i) -OH,

[0345] ü) -O-M'+ with M'+,

[0346] iii) n in which,

[0347] • p is equal to 0 or 2;

[0348] •m' is worth 0 or 1;

[0349] • X' represents an oxygen atom; and

[0350] M+, M'+ and M”+ are identical and chosen from sodium or potassium.

[0351] According to one embodiment of the present invention, wherein in the (2) reducing agent of formula (II)

[0352] X of formula (II) represents sulfur;

[0353] m in formula (II) equals 1;

[0354] M+ in formula (II) is sodium or potassium;

[0355] R of formula (II) represents a group chosen from

[0356] i. -OH, and

[0357] H. -OM'+ with M'+,

[0358] M+ and M+ are identical

[0359] According to one embodiment, the compounds of formula (II) can be found in their marginal or delocalized mesomeric limiting forms,

[0360] when m = 0, then RS(0 M+)=0 <- -> RS(=0)-0 M+ and

[0361] when m = 1, the mesomeric limiting forms are

[0362] RS(O M+)(=X)m=O <- -> RS(=0)(=X)m-0 M+ <- -> RS(=O)(X M+)m=O

[0363] where, M+, M'+, M"+ are present to ensure the electroneutrality of the molecule of formula (II).

[0364] In a preferred embodiment of the present invention, the (2) reducing agent may be selected from sodium bisulfite, sodium metabisulfite, sodium sulfite, sodium thiosulfate, sodium sulfate, potassium metabisulfite, potassium sulfite, potassium thiosulfate, potassium sulfate or potassium tetrathionate.

[0365] According to another preferred embodiment of the present invention, the (2) reducing agent may be selected from sodium bisulfite, sodium metabisulfite, sodium sulfite, sodium thiosulfate, or sodium sulfate.

[0366] According to one embodiment of the present invention, the quantity of (2) reducing agent in the composition may be 0.01% by weight or more, preferably 0.02% by weight or more, and more preferably 0.03% by weight or more, relative to the total weight of the composition.

[0367] According to one embodiment of the present invention, the quantity of (2) reducing agent in the composition may be 2.0% by weight or less, preferably 1.0% by weight or less, and more preferably 0.05% by weight or less, relative to the total weight of the composition.

[0368] According to one embodiment of the present invention, the quantity of (2) reducing agent in the composition according to the present invention can be from 0.01% to 2% by weight, preferably from 0.02% to 1.0% by weight, and more preferably from 0.03% to 0.5% by weight, relative to the total weight of the composition. Arginine

[0369] According to one embodiment of the present invention, the composition comprises (3) arginine.

[0370] According to one embodiment of the present invention, the amount of (3) arginine in the composition may be 0.01% by weight or more, preferably 0.1% by weight or more, and more preferably 0.2% by weight or more, relative to the total weight of the composition.

[0371] According to one embodiment of the present invention, the amount of (3) arginine in the composition may be 10.0% by weight or less, preferably 8.0% by weight or less, and more preferably 6.0% by weight or less, relative to the total weight of the composition.

[0372] According to one embodiment of the present invention, the quantity of (3) arginine in the composition according to the present invention can be from 0.01% to 10% by weight, preferably from 0.1% to 8% by weight, and more preferably from 0.2% to 6% by weight, relative to the total weight of the composition. pH correcting agent

[0373] According to one embodiment of the present invention, the composition may comprise at least one pH corrector. Two or more pH correctors may be used in combination. Thus, a single type of pH corrector or a combination of different types of pH correctors may be used.

[0374] As a pH correcting agent, at least one acidifying agent and / or at least one alkalizing agent may be used.

[0375] The acidifying agent may be a monovalent or polyvalent acid, such as divalent.

[0376] Acidifying agents may be, for example, mineral (inorganic) acids such as hydrochloric acid, sulfuric acid, phosphoric acid, or organic acids such as carboxylic acids, for example tartaric acid, citric acid and lactic acid, as well as sulfonic acids.

[0377] The alkalizing agent may be a monovalent or polyvalent base, such as divalent. Alkalizing agents may be mineral (inorganic) or organic, or hybrid.

[0378] Mineral alkalizing agents may be selected from aqueous ammonia; alkali metal carbonates or bicarbonates such as sodium or potassium carbonates and sodium or potassium bicarbonates; alkali metal hydroxides such as sodium hydroxide and potassium hydroxide; and mixtures thereof.

[0379] Organic alkalizing agents may be selected from organic amines having a pKb at 25 °C of less than 12, preferably less than 10, and even more advantageously less than 6. It should be noted that this is the pKb corresponding to the highest basicity functional group. Furthermore, the organic amines do not include any alkyl or alkenyl fatty chain comprising more than ten carbon atoms.

[0380] The organic alkalizing agent may be chosen, for example, from alkanolamines, oxyethylenated and / or oxypropylenated ethylenediamines, amino acids and amine compounds of formula (III) below: A(III) nw-ln" RJ

[0381] in which

[0382] W represents a divalent Ci-C6 alkylene radical optionally substituted by one or more hydroxyl groups or a Ci-C6 alkyl radical, and optionally interrupted by one or more heteroatoms such as O and N, and

[0383] Rx, Ry, Rz and Rt, which may be identical or different, represent a hydrogen atom or an alkyl radical in Ci-C6, hydroxyalkyl in Ci-C6 or aminoalkyl in CrC6.

[0384] Examples of amine compounds of formula (III) that may be mentioned include 1,3-diaminopropane, 1,3-diamino-2-propanol, spermine and spermidine.

[0385] The term "alkanolamine" designates an organic amine comprising a primary, secondary or tertiary amine function, and one or more linear or branched Ci-C8 alkyl groups bearing one or more hydroxyl radicals.

[0386] Alkanolamines such as monoalkanolamines, dialcanolamines or trialcanolamines comprising one to three identical or different Ci-C4 hydroxyalkyl radicals may be suitable for the present invention. Among compounds of this type, one may cite monoethanolamine (MEA), diethanolamine, triethanolamine, monoisopropanolamine, diisopropanolamine, N-dimethylaminoethanolamine, 2-amino-2-methyl-l-propanol, triisopropanolamine, 2-amino-2-methyl-l,3-propanediol, 3-amino-l,2-propanediol, 3-dimethylamino-l,2-propanediol and tris(hydroxymethylamino)methane.

[0387] The amino acids that may be used are of natural or synthetic origin, in their L, D or racemic form, and comprise at least one acid function chosen more particularly from among the carboxylic acid, sulfonic acid, phosphonic acid or phosphoric acid functions. The amino acids may be in neutral or ionic form.

[0388] Amino acids that can be used in the present invention include, in particular, aspartic acid, glutamic acid, alanine, arginine, ornithine, citrulline, asparagine, carnitine, cysteine, glutamine, glycine, histidine, lysine, isoleucine, leucine, methionine, N-phenylalanine, proline, serine, taurine, threonine, tryptophan, tyrosine and valine.

[0389] It may be preferable for the amino acids to be basic amino acids comprising an additional amine function optionally included in a ring or in a ureido function.

[0390] Such basic amino acids may preferably be chosen from those corresponding to formula (IV) below: / MH., <IV) RCH . —CH % * COjH

[0391] in which

[0392] R of formula (IV) represents a group chosen from:

[0393] -(CH2)3-NH2,

[0394] -(CH2)2-NH2,

[0395] -(CH2)2-NH-CO-NH2, and

[0396] Compounds corresponding to formula (IV) include histidine, lysine, arginine, omithine and citrulline.

[0397] The organic alkalizing agent can be chosen from among heterocyclic organic amines. In addition to histidine, which has already been mentioned among the amino acids, pyridine, piperidine, imidazole, triazole, tetrazole, and benzimidazole may be mentioned in particular.

[0398] The organic alkalizing agent can also be chosen from amino acid dipeptides. Examples of amino acid dipeptides that can be used in the present invention include carnosine, anserine, and balein.

[0399] The organic alkalizing agent can also be chosen from compounds comprising a guanidine function. As amines of this type that can be used in the present invention, in addition to arginine, which has already been mentioned as an amino acid, creatine, creatinine, 1,1-dimethylguanidine, 1,1-diethylguanidine, glycocyamine, metformin, agmatine, N-amidinoalanine, 3-guanidinopropionic acid, 4-guanidinobutyric acid and 2-([amino(imino)met hyl]amino)ethane-1-sulfonic acid.

[0400] In a preferred embodiment of the present invention, the organic alkalizing agent may be selected from amino acids, preferably basic amino acids, and more preferably, arginine, lysine, histidine, or mixtures thereof. Even more preferably, the organic alkalizing agent may be arginine.

[0401] Hybrid compounds that may be mentioned include salts of the amines mentioned above with acids such as carbonic acid or hydrochloric acid. Guanidine carbonate or monoethanolamine hydrochloride may be used in particular.

[0402] According to one embodiment of the present invention, the amount of the pH correcting agent in the composition may be equal to 0.01% by weight or more, of preferably 0.05% by weight or more, and more preferably 0.1% by weight or more, relative to the total weight of the composition.

[0403] According to one embodiment of the present invention, the amount of pH correcting agent in the composition may be equal to 15% by weight or less, preferably 10% by weight or less and, more preferably, 5% by weight or less, relative to the total weight of the composition.

[0404] According to one embodiment of the present invention, the pH correcting agent may be present in an amount from 0.01% to 15% by weight, preferably from 0.05% to 10% by weight, and more preferably from 0.1% to 5% by weight or less, relative to the total weight of the composition.

[0405] It is preferable that the composition according to the present invention has a pH of 4.5 or more, and more preferably of 5 or more.

[0406] It is preferable that the composition according to the present invention has a pH of 6.5 or less, and more preferably of 6 or less.

[0407] It is preferable that the composition according to the present invention has a pH of 4.5 to 6.5, and more preferably of 5 to 6.

[0408] The pH of the composition corresponds to the pH of the aqueous phase of the composition according to the present invention.

[0409] It may be preferable that at least one buffer or buffering agent also be used, as a pH correcting agent, in combination with the acidifying agent and / or the alkalizing agent, in order to stabilize the pH of the composition according to the present invention.

[0410] Any commonly known buffer may be used. For example, salts of acids or bases, preferably salts of weak acids or weak bases, may be used. For example, sodium citrate or sodium lactate may be used as a buffer if citric acid or lactic acid is used as the acidifying agent. Water

[0411] According to one embodiment of the present invention, the composition may advantageously comprise at least one medium / solvent, including water and / or an organic medium / solvent.

[0412] According to one embodiment of the present invention, the composition may comprise water in varying amounts. For low-viscosity applications of the composition, for example as a leave-on lotion, a relatively high amount of water may be used. For example, water is used at a content greater than or equal to 20% by weight relative to the total weight of the composition. The water content in the low-viscosity composition according to the invention preferably ranges from 20% to 99% by weight, or preferably from 30% to 95% by weight, or from 40% to 90% by weight, relative to the total weight of the composition. For high-viscosity applications For a high viscosity composition, for example in the form of a leave-on cream, a relatively smaller quantity of water can be used. The high viscosity composition according to the invention advantageously comprises water at a concentration less than or equal to 40% by weight relative to the total weight of the composition.

[0413] According to one embodiment of the present invention, the amount of water in the composition may be present in an amount of 20% by weight or less, preferably 30% by weight or less, and more preferably 40% by weight or less, relative to the total weight of the composition.

[0414] According to one embodiment of the present invention, the amount of water in the composition may be present in an amount of 99% by weight or less, preferably 95% by weight or less, and more preferably 90% by weight or less, relative to the total weight of the composition.

[0415] According to one embodiment of the present invention, the quantity of water in the composition according to the present invention can be from 20% to 99% by weight, preferably from 30% to 95% by weight, and more preferably from 40% to 90% by weight, relative to the total weight of the composition.

[0416] The composition according to the invention may also include one or more organic media / solvents, preferably organic media / solvents soluble in water (solubility greater than or equal to 5% in water at 25°C and atmospheric pressure).

[0417] Examples of organic media / solvents that may be cited include alcohols: in particular monovalent alcohols such as ethyl alcohol, isopropyl alcohol, benzyl alcohol and phenylethyl alcohol; diols such as ethylene glycol, propylene glycol and butylene glycol; other polyols such as glycerol, a sugar and sugar alcohols; and ethers such as monomethyl, monoethyl and monobutyl ethers of ethylene glycol, monomethyl, monoethyl and monobutyl ethers of propylene glycol, and monomethyl, monoethyl and monobutyl ethers of butylene glycol.

[0418] The organic media / solvents, if any, are present in an amount ranging from 0.1% to 40% by weight, preferably from 1% to 30% by weight, or from 5% to 20% by weight, relative to the total weight of the composition according to the invention.

[0419] According to one embodiment of the present invention, the composition lightens or depigments a keratinous material, preferably the skin.

[0420] According to one embodiment of the present invention, the composition can be useful for bleaching or depigmenting keratinous material, preferably skin. Preparation of the composition

[0421] According to one embodiment of the present invention, a process for preparing the composition is proposed. The process includes mixing the components essential and optional components described above can be prepared by any known method. In one embodiment, the composition of the present invention can be prepared by a process including the steps of: mixing at least one compound of formula (I) or (!'), at least one reducing agent, and arginine with water. The mixing includes, if necessary, the addition of other additives. The process involves mixing the components at any temperature, preferably at room temperature, more preferably at 30°C or above, at 40°C or above, and more preferably at 50°C or above.

[0422] The compositions according to the invention can be manufactured by known processes, generally used in the cosmetic or dermatological field.

[0423] The composition according to the present invention may be in various forms, but not limited to, an emulsion, a solution, a gel or a cream. Method / Use of the composition

[0424] According to one embodiment, the present invention proposes a cosmetic process for treating keratinous material, the process comprising: the application of the composition of the present invention to the keratinous material, preferably the skin.

[0425] According to one embodiment, the present invention proposes a non-therapeutic method for treating keratinous material, the method comprising: the application of the composition of the present invention to the keratinous material, preferably the skin.

[0426] According to one embodiment, the present invention provides a use for the composition to lighten or depigment keratinous material, preferably skin. In another embodiment, the composition is suitable for treating darker and / or more pigmented spots on the skin. In yet another embodiment, the composition is useful for providing necessary skin care, preferably for lightening the skin and / or reducing or lightening darker and / or more pigmented spots on the skin.

[0427] The composition according to the present invention is a cosmetic composition that can be applied once a day, twice a day, or more than once or twice a day. In some cases, the composition is applied in the evening before bedtime. In other cases, the compositions are applied in the morning. In still other cases, the composition can be applied immediately after washing the skin. The compositions can be used once, or for a series of days, weeks, or months. For example, the compositions can be used daily for a period of 1, 2, 3, 4, 5, 6, 7, 8 weeks or more, or for months.

[0428] According to one embodiment, the present invention proposes the use of a combination of:

[0429] (i) at least one reducing agent of formula (II), its mesomeric forms and its solvates such as hydrates (II)

[0431] in which,

[0432] X represents a heteroatom chosen from oxygen or sulfur, preferably oxygen;

[0433] m is equal to 0 or 1;

[0434] M+ is a cation, preferably chosen from an alkali metal, an alkaline earth metal or an ammonium, more preferably chosen from an alkali metal such as sodium or potassium;

[0435] R represents a group chosen from:

[0436] i) -OH,

[0437] ü) -O-M'+ with M'+ as defined previously for M+,

[0438] iii) Q in which, 1¾

[0439] • p is an inclusive integer chosen between 0 and 4, preferably 0, 1, 2 and more preferably 0 or 2;

[0440] • m' is worth 0 or 1, preferably 1;

[0441] • X' is such that defined for X, preferably X' represents an oxygen atom; and

[0442] • M' '+ is such as defined previously for M+, and M+, M'+, M”+ are identical or different, preferably identical and

[0443] (ii) of arginine,

[0444] in a composition comprising at least one compound selected from the compounds of formula (I), its tautomer of formula (I'), their salts, optical isomers, racemates, solvates, hydrates, or mixtures thereof: OO (Q (O

[0445] formulas (I) and (I') in which:

[0446] - R i designates a radical chosen from:

[0447] a) a hydrogen atom;

[0448] b) a linear saturated alkyl group in the form of Ci-Cio or branched in the form of C3-CiO optionally substituted by one or more groups, which may be identical or different, selected from:

[0449] i) -O-R3;

[0450] ii) -S-R3;

[0451] - R 2 denotes a radical chosen from:

[0452] a) a hydrogen atom;

[0453] b) a linear saturated CrCi2 or C3-Ci2 branched or C3-C8 cyclic hydrocarbon group optionally substituted by one or more groups, which may be identical or different, selected from:

[0454] i) -O-R3;

[0455] ii) -S-R3;

[0456] iii) -C(O)-O-R3 ;

[0457] iv) an aryl group at C5-Ci2, optionally substituted by one or more hydroxyls and / or by one or more alkoxy radicals in Ci-C8;

[0458] c) an aryl group in C5-Ci2, optionally substituted by one or more hydroxyl groups and / or by one or more CrC8 alkoxy radicals; and

[0459] - R 3 designates a radical chosen from:

[0460] a) a hydrogen atom;

[0461] b) a linear saturated alkyl group in the form of Ci-Cio or branched in the form of C3-CiO,

[0462] to stabilize the compound of formula (I), its tautomer of formula (I1), the salts, solvates, hydrates, optical isomers, racemates, or mixtures thereof, in the composition.

[0463] The term “stabilize” has the same meaning as strengthening stability.

[0464] According to one embodiment of the present invention, the combination of at least one reducing agent and arginine stabilizes the compound of formula (I) or (I1) in the composition. In a particular embodiment, the composition according to the present invention exhibits increased stability of the thiopyridinone compound of formula (I) and (I1) that it contains. In one embodiment, the composition according to the present invention exhibits increased stability of the compound of formula (I) or (I1) when stored for a longer period of time at room temperature. In another embodiment, the composition according to the present invention shows increased stability, and preferably increased photostability, of the compound of formula (I) or (I1) when the composition is exposed to light.In yet another embodiment, the increased stability, and preferably the increased photostability, of the compound of formula (I) or (I1) in the composition provides improved bioavailability. to confer prolonged lightening or depigmenting effects on keratinous matter. EXAMPLES

[0465] The disclosure will now be illustrated by practical examples, which are intended to demonstrate the operation of the disclosure and are not intended to impose restrictive limitations on the scope of this disclosure. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those commonly understood by a person skilled in the art of this disclosure. Although processes and materials similar or equivalent to those described herein may be used in practice for the disclosed processes and compositions, examples of processes, devices, and materials are described herein. It should be understood that this disclosure is not limited to any particular composition, processes, and experimental conditions described, to the extent that such processes and conditions may be applicable. The present invention will be described in more detail by means of examples.However, these examples should not be interpreted as limiting the scope of the present invention. Example 1#: Synthesis of compound #20

[0466] Compound 20 is synthesized as disclosed in Example 2 of patent EP3 390 363. Example 2#:

[0467] Compositions for skin whitening and depigmentation

[0468] Composition A (according to the invention) was prepared from the ingredients as described in Table 1 below. 0.50% by weight of compound 20 of formula (I), i.e., 2-mercaptonicotinoyl glycine, 0.20% by weight of sodium thiosulfate, 0.50% by weight of arginine, 0.60% by weight of thickeners, 1.00% by weight of preservatives, and other components as mentioned in Table 1, as well as water in the required quantity, were mixed together to obtain Composition A. Similarly, Composition B (according to the invention), comprising 3.00% by weight of arginine and other components as mentioned in Table 1, was also prepared.

[0469] [Tables 1] INCI composition (% by weight) AB 2-Mercaptonicotinoyl Glycine 0.50 0.50 Sodium Thiosulfate (Sodium thiosulfate) 0.20 0.20 Arginine 0.50 3.00 Thickeners 0.60 0.60 Preservatives 1.00 1.00 Alcohol Denatured 4.00 4.00 Water 69.83 66.90 Glycols 6.00 6.00 Laureth-4 0.50 0.50 Polyglyceryl-4 Caprate 1.00 1.00 Silicone Oils 4.20 4.20 Active Ingredients 10.30 10.30 Caffeine 1.00 1.00 Chelating Agent 0.30 0.30 Citric Acid 0.07 0.50 Example 3#: Photostability of compositions

[0470] The compositions prepared in Example 1 were analyzed to determine their photostability upon exposure to UV radiation.

[0471] Each of the inventive compositions A and B was independently applied as a coating to an inert substrate. The coated substrates were exposed to UV radiation of 5 J / cm² for approximately 1 hour. The exposed compositions were then dissolved in a solvent (organic solvent) and the solutions were analyzed by HPLC or UPLC chromatographic processes.

[0472] The quantity of compound 20 of formula (I) in each of the compositions was measured by HPLC-UV assay at two time points as mentioned below.

[0473] Instant (1): Just after the composition has been prepared

[0474] Instant (2): Solution of compositions after exposure to UV.

[0475] The details of the HPLC-UV assays are as follows:

[0476] Apparatus / Reagents

[0477] [Tables2] High-performance liquid chromatography (UPLC) system, RP18 HPLC column, 1.7, 2.1 mm x 100 mm, Eluent A: 0.1% phosphoric acid Eluent B Methanol

[0478] HPLC Conditions

[0479] [Tables3] UV detector 296 nm Column temp. 30°C Flow rate 0.4 ml / min Injection volume 1 µL Mobile phase Gradient mode A: Phosphoric acid 0.1% in water B: Methanol

[0480] The quantity of compound 20 of formula (I) remaining in each of the compositions before (Time 1) and after exposure to UV (Time 2) was determined by HPLC-UV assay and the difference in quantity of compound of formula (I) was calculated.

[0481] The % values ​​of compound 20 of formula (I), remaining in compositions A and A exposed to UV, are presented in the table below.

[0482] [Tables4] Composition Compound 20 of formula (I) remaining after UV exposure (% by weight) A (inventive) 80% B (inventive) 86%

[0483] It was found that compositions A and B, which included arginine, were more effective and more stable even under exposure to UV radiation. With compositions A and B containing 0.5 wt% and 3 wt% arginine, respectively, the stabilization of compound 20 was increased in the composition. Thus, the composition according to the present invention, comprising arginine, provided a stable composition with an increased shelf life.< / x>

Claims

Demands

1. Composition, preferably a cosmetic composition, comprising: i) at least one compound selected from a compound of formula (I) below, its tautomer of formula (!') below, their salts, solvates, hydrates, optical isomers, racemates or mixtures thereof: 0 0 A ~ A z' N- * y 'Ay N' " Vs'S 1 'NS 1 M » H Formula (!) Formula (1) wherein, - R i denotes a radical selected from: a) a hydrogen atom; b) a linear saturated alkyl group in C1-C10 or branched in C3-C10 optionally substituted by one or more groups, which may be identical or different, selected from: i) -O-R3; ii) -S-R3; - R 2 denotes a radical selected from: a) a hydrogen atom;b) a linear saturated hydrocarbon group in C1-C12 or branched in C3-C12 or cyclic in C3-C8, optionally substituted by one or more groups, which may be identical or different, selected from i) -O-R3; ü) -S-R3; iii) -C(O)-O-R3; iv) a C5-C12 aryl group, optionally substituted by one or more hydroxyl groups and / or by one or more Ci-C8 alkoxy radicals and c) a C5-C12 aryl group, optionally substituted by one or more hydroxyl groups and / or with one or more CrC8 alkoxy radicals; - R3 denotes a radical selected from: a) a hydrogen atom and b) a linear saturated alkyl group in C1-C10 or branched in C3-C10; ii) at least one reducing agent of formula (II), its mesomeric forms and its solvates such as hydrates O (II) [XU in which X represents a heteroatom selected from oxygen or sulfur, preferably oxygen; m is 0 or 1; M+ is a cation, preferably selected from an alkali metal, an alkaline earth metal or an ammonium, more preferably selected from an alkali metal such as sodium or potassium; R represents a group selected from: i) -OH, ii) -O-M'+ with M'+ as defined above for M+, iii) in which, ixL> • p is an inclusive integer selected from 0 to 4, preferably 0, 1, 2 and more preferably 0 or 2; • m' is 0 or 1, preferably 1; • X' is as defined for X, preferably X' represents an oxygen atom; and • M”+ is such as defined previously for M+, and M+, M'+, M”+ are identical or different, preferably identical; and iii) of arginine.

2. Composition according to claim 1, wherein: compound (I) is selected from compounds 1 to 24, their tautomers, salts, solvates, hydrates, optical isomers, racemates or mixtures thereof, in particular compounds 1, 2, 4, 6, 7, 9, 11, 12, 14, 15, 16, 17, 18, 19, 20 or 21, more particularly 1, 9, 16, 18, 19, 20 or 21, preferably 18, 19, 20 or 21, and more preferably 20: ■'? -. N-bsnzÿ?-2-«rôxtî-l,2^W*opyôtoe-■3-cæfeœçaraâie QtS5S-7O-§ 5 fl T ,, Np^ényPS-thsox.o- 1 ^-iHiÿiàraf^ràfeie-3-caftaarajde 184^7-16-1 S J.,......< J ' XN"':<■ V- <W*<Wrêtëne- 3-caïtoxarasEfe 91853-73-3 7 a:v' jr ^R-<4-mé^:ypftéïJÿl) âWÆ-ï-ihisxo-1.2-®ysra£<^ 3-ca&oxæWe 923SS2-SS-S 8 in j. iyy -- M-(2-^éftySpropÿi;H 2-81I0Ï0-l,2^ÿ#cpyr»te-3-cæboxamicis 1108027-79-3 SJ ..... ,, xr..... N-pentïsî1-2'thk)xc-3W- 1 Xwæcfis No. 330807-57-7 18 p. . T If M-ncnyl-2-teKO-V-®ydrapyïWs-3-carfcûxamâfe 1031149-44-6 11 ) ........V„, '.y. X <): / / z:z. ( s ^(2-Sy<1yrax? / éthy1s-2-yrap-2-We-Sü1 3rC«&œ£®ffl«fe 12 <} , JL ,-x il'V bÿ 2^œeféaptoæ®1mamide 13 L XI......x.....» ?s >s 2-hyslroxyéihyH- 2-to®- V-®T / cartaWWneî-3 14 j 1 ». ,r ,. YYS <> N-(2.,3-®ydFoxypîspyft-2-^isxo- 1 ..î-dstiÿï&op'ÿTsdsn®-3-caîfcoxamide 15 - <s' ! .-. ,À . Oh X’- ••-'■' '• 'xj X YX ' » N-(1.3-d^hydEoxypfspan- 2-yl> 2-ttBQK0- 12-dày6ropyï1dsn&- 3*€Brt»xara <je 16 ,. I T ... rir i " ? N-[s2-thsoxa- 5 2 d!fru 3-y 1 ^artwSkT slwia^ d e&îyfe 17 ç N-K2-thteçs-12-dstiysfi'opÿïldÉn- 18 QXT 1> ®ycWWn-d'é&syte 18 ... 1 , XT o- T .X-- ? 2-dihysjopyïldjn-d é^vte 26 _ 1 _ > ¥ N-[{2-ftsoxs-1,2-dstiydropy s'idm-3-ÿt>cartwfSÿ®^ne

3.

4.

5. Composition according to claim 1 or 2, wherein the compound of formula (I) or its tautomer of formula (I'), its salts, solvates, hydrates, optical isomers, racemates, or mixtures thereof, is in an amount from 0.01% to 10% by weight, preferably from 0.05% to 5% by weight, and more preferably from 0.1% to 3% by weight, relative to the total weight of the composition. Composition according to any one of the preceding claims, wherein: X of formula (II) represents sulfur; m in formula (II) equals 1; M+ in formula (II) is sodium or potassium; R in formula (II) represents a group chosen from i) -OH, and ii) -O-M'+ with M'+, M+ and M+ are identical. Composition according to any one of the preceding claims, wherein the reducing agent is selected from bisulfite of sodium, sodium metabisulfite, sodium sulfite, sodium thiosulfate or sodium sulfate.

6. Composition according to any one of the preceding claims, wherein the reducing agent is present in an amount from 0.01% to 2% by weight, preferably from 0.02% to 1.0% by weight, and more preferably from 0.03% to 0.5% by weight, relative to the total weight of the composition.

7. Composition according to any one of the preceding claims, wherein arginine is present in an amount from 0.05% to 10% by weight, preferably from 0.1% to 8% by weight, and more preferably from 0.2% to 6% by weight, relative to the total weight of the composition.

8. Cosmetic process for treating keratinous material, the process comprising: applying the composition according to any one of the preceding claims to the keratinous material, preferably the skin.

9. Use of the composition according to any one of claims 1 to 8 for lightening or depigmenting keratinous material, preferably skin.

10. Use of a combination of (i) at least one reducing agent of formula (II), its mesomeric forms and its solvates such as hydrates fi (H) ■ < —.................Zj R / 1 rc - - r - o - ?v! wherein, X represents a heteroatom selected from oxygen or sulfur, preferably oxygen; m is 0 or 1; M+ is a cation, preferably selected from an alkali metal, an alkaline earth metal or an ammonium, more preferably selected from an alkali metal such as sodium or potassium; R represents a group selected from: i) -OH, ii) -O-M'+ with M'+ as defined above for M+ and iü) n in which, h little • p is an inclusive integer chosen between 0 and 4, preferably 0, 1, 2 and more preferably 0 or 2; • m' is worth 0 or 1, preferably 1; • X' is such that defined for X, preferably X' represents an oxygen atom; and • M”+ is such as defined previously for M+, and M+, M'+, M”+ are identical or different, preferably identical and (ii) arginine, in a composition comprising at least one compound selected from the compounds of formula (I), its tautomer of formula (I1), their salts, optical isomers, racemates, solvates, hydrates, or mixtures thereof: OO (1} (O formulas (I) and (F) in which: - R i designates a radical chosen from: a) a hydrogen atom; b) a linear saturated alkyl group in the form of Ci-Cio or branched in the form of C3-CiO optionally substituted by one or more groups, which may be identical or different, chosen from: i) -O-R3; ii) -S-R3; - R 2 designates a radical chosen from: a) a hydrogen atom; b) a linear saturated hydrocarbon group in C1-C12 or branched in C3-C12 or cyclic in C3-C8, optionally substituted by one or more groups, which may be identical or different, chosen from: i) -O-R3 ii) -S-R3 iü) -C(O)-O-R3 ; (iv) an aryl group in C5-Ci2, optionally substituted by one or more hydroxyl groups and / or by one or more alkoxy radicals in Ci-C8; c) an aryl group at C5-C12, optionally substituted by one or more hydroxyl groups and / or by one or more alkoxy radicals at C1-C8; and - R 3 designates a radical chosen from: a) a hydrogen atom; b) a linear saturated alkyl group in C1-C10 or branched in C3-C10, to stabilize the compound of formula (I), its tautomer of formula (P), their salts, solvates, hydrates, optical isomers, racemates, or mixtures thereof, in the composition.